IGF-IEc expression is associated with advanced clinical and pathological stage of prostate cancer

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2441-2446

  Savvani, Argyro ^a   Petraki, Constantina ^a,b   Msaouel, Pavlos ^a,c   Diamanti, Evangelia ^a   Xoxakos, Ioannis ^a   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Metropolital Hospital   (Greece)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

IGF1Ec; Immunohistochemistry; Insulin like growth factor 1 (IGF 1); Mechano growth factor (MGF); Prostate cancer

Indexed keywords

FORMALDEHYDE; INSULIN LIKE GROWTH FACTOR 1EC; PARAFFIN; SOMATOMEDIN; UNCLASSIFIED DRUG; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; CANCER GRADING; IGF1EC; INSULIN-LIKE GROWTH FACTOR 1 (IGF-1); MECHANO-GROWTH FACTOR (MGF); METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TISSUE FIXATION;

IGF1EC; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR 1 (IGF-1); MECHANO-GROWTH FACTOR (MGF); PROSTATE CANCER;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; MALE; NEOPLASM GRADING; NEOPLASM STAGING; PARAFFIN EMBEDDING; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; TISSUE FIXATION;

MLCS; MLOWN;

EID: 84881360817     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Philippou A, Maridaki M, Halapas A and Koutsilieris M: The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 21: 45-54, 2007.
2. Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28: 20-47, 2007.
3. Koutsilieris M, Mitsiades C and Sourla A: Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: Development of anti-survival factor therapy for hormone-refractory prostate cancer. Mol Med 6: 251-267, 2000.
4. Koutsilieris M and Polychronakos C: Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res 12: 905-910, 1992.
5. Armakolas A, Philippou A, Panteleakou Z, Nezos A, Sourla A, Petraki C and Koutsilieris M: Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells. Prostate 70: 1233-1242, 2010.
6. Philippou A, Halapas A, Maridaki M and Koutsilieris M: Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact 7: 208-218, 2007.
7. Philippou A, Armakolas A, Panteleakou Z, Pissimissis N, Nezos A, Theos A, Kaparelou M, Armakolas N, Pneumaticos SG and Koutsilieris M: IGF1Ec expression in MG-63 human osteoblast-like osteosarcoma cells. Anticancer Res 31: 4259-4265, 2011.
8. Stavropoulou A, Halapas A, Sourla A, Philippou A, Papageorgiou E, Papalois A and Koutsilieris M: IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med 15: 127-135, 2009.
9. Philippou A, Papageorgiou E, Bogdanis G, Halapas A, Sourla A, Maridaki M, Pissimissis N and Koutsilieris M: Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo 23: 567-575, 2009.
10. Philippou A, Stavropoulou A, Sourla A, Pissimissis N, Halapas A, Maridaki M and Koutsilieris M: Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain. In Vivo 22: 27-35, 2008.
11. Theophanous E, Petraki C, Scorilas A, Komborozos V, Veloudis G, Varga JL, Zarandi M, Schally AV and Koutsilieris M: The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol Med 15: 242-247, 2009.
12. McCarty KS, Jr., Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigier HF and McCarty KS Sr.: Use of a monoclonal antiestrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46: 4244s-4248s, 1986.
13. R Development Core Team. R: A language and environment for statistical computing. In: R Foundation for Statistical Computing, Vienna, Austria, 2012.
14. Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer 12: 159-169, 2012.
15. Bach LA, Fu P and Yang Z: Insulin-like growth factor-binding protein-6 and cancer. Clin Sci 124: 215-229, 2013.
16. Biernacka KM, Perks CM and Holly JM: Role of the IGF axis in prostate cancer. Minerva Endocrinol 37: 173-185, 2012.
17. Halje M, Nordin M, Bergman D and Engstrom W: Review: The effect of insulin-like growth factor II in the regulation of tumour cell growth in vitro and tumourigenesis in vivo. In Vivo 26: 519-526, 2012.
18. Weroha SJ and Haluska P: The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 41: 335-350, vi, 2012.